UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended June 30, 2018
or
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number:
000-50679
CORCEPT THERAPEUTICS INCORPORATED
(Exact Name of Corporation as Specified in Its Charter)
Delaware | 77-0487658 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
149 Commonwealth Drive
Menlo Park, CA 94025
(Address of principal executive offices, including zip code)
(650) 327-3270
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
| ☒ |
| Accelerated filer |
| ☐ |
Non-accelerated filer |
| ☐ (Do not check if a small reporting company) |
| Smaller reporting company |
| ☐ |
Emerging growth company |
| ☐ |
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
On August 3, 2018, there were 116,051,242 shares of common stock outstanding at a par value of $0.001 per share.
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION |
| 3 |
ITEM 1. FINANCIAL STATEMENTS |
| 3 |
CONDENSED CONSOLIDATED BALANCE SHEETS |
| 3 |
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME |
| 4 |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
| 5 |
NOTES TO CONDENSED FINANCIAL STATEMENTS |
| 6 |
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
| 15 |
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
| 19 |
ITEM 4. CONTROLS AND PROCEDURES |
| 19 |
PART II. OTHER INFORMATION |
| 20 |
ITEM 1. LEGAL PROCEEDINGS |
| 20 |
ITEM 1A. RISK FACTORS |
| 20 |
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
| 32 |
ITEM 3. DEFAULTS UPON SENIOR SECURITIES |
| 32 |
ITEM 4. MINE SAFETY DISCLOSURES |
| 32 |
ITEM 5. OTHER INFORMATION |
| 32 |
ITEM 6. EXHIBITS |
| 33 |
SIGNATURES |
| 34 |
2